Legend Biotech

General Information


We are a global, clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 650 employees in the United States, China and Europe, our differentiated technology, global development and manufacturing strategy and expertise provide us with the ability to generate, test and manufacture next-generation cell therapies targeting indications with high unmet needs. Our lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy we are jointly developing with our strategic partner, Janssen Biotech, Inc., or Janssen, for the treatment of multiple myeloma, or MM.

Employees: 645
Founded: 2014
Contact Information
Address 2101 Cottontail Lane, Somerset, NJ 08873, US
Phone Number (732) 317-5050
Web Address http://www.legendbiotech.com
View Prospectus: Legend Biotech
Financial Information
Market Cap $2961.1mil
Revenues $58.8 mil (last 12 months)
Net Income $-164.8 mil (last 12 months)
IPO Profile
Symbol LEGN
Exchange NASDAQ
Shares (millions): 18.4
Price range $23.00 - $23.00
Est. $ Volume $423.8 mil
Manager / Joint Managers Morgan Stanley/ J.P. Morgan/ Jefferies
CO-Managers -
Expected To Trade: 6/5/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change